Journal
PEDIATRIC BLOOD & CANCER
Volume 67, Issue 5, Pages -Publisher
WILEY
DOI: 10.1002/pbc.28249
Keywords
acute lymphoblastic leukemia; chimeric antigen receptor t-cell; communication; interdisciplinary care; palliative care; pediatric oncology; psychosocial; symptom management
Categories
Funding
- National Heart, Lung, and Blood Institute [5T32CA009351-40]
- NATIONAL CANCER INSTITUTE [ZIDBC011517] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). However, this new paradigm has introduced unique considerations specific to the patients receiving CAR T-cell therapy, including prognostic uncertainty, symptom management, and psychosocial support. With increasing availability, there is a growing need for evidence-based recommendations that address the specific psychosocial needs of the children who receive CAR T-cell therapy and their families. To guide and standardize the psychosocial care offered for patients receiving CAR T-cell therapy, we propose the following recommendations for addressing psychosocial support.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available